+1 credit
| Version | Summary | Created by | Modification | Content Size | Created at | Operation |
|---|---|---|---|---|---|---|
| 1 | Vicky Zhou | + 399 word(s) | 399 | 2020-12-15 07:46:13 |
Video Upload Options
Bruton tyrosine kinase
1. Normal Function
The BTK gene provides instructions for making a protein called Bruton tyrosine kinase (BTK), which is essential for the development and maturation of B cells. B cells are specialized white blood cells that help protect the body against infection. These cells can mature into cells that produce special proteins called antibodies or immunoglobulins. Antibodies attach to specific foreign particles and germs, marking them for destruction. The BTK protein transmits important chemical signals that instruct B cells to mature and produce antibodies.
2. Health Conditions Related to Genetic Changes
2.1. Isolated Growth Hormone Deficiency
A few mutations in the BTK gene have been found to cause isolated growth hormone deficiency type III, a condition characterized by slow growth, short stature, and a weakened immune system. Mutations that cause this condition lead to production of a nonfunctional version of the BTK protein. People with isolated growth hormone deficiency are prone to infections because they produce very few B cells and have a shortage of antibodies (agammaglobulinemia). A lack of the BTK protein is likely responsible for the immune system symptoms, but how a shortage of BTK protein causes short stature in affected individuals is unclear.
2.2. X-Linked Agammaglobulinemia
More than 600 different mutations in the BTK gene have been found to cause X-linked agammaglobulinemia (XLA). Most of these mutations result in the absence of the BTK protein. Other mutations change a single protein building block (amino acid), which probably leads to the production of an abnormal BTK protein that is quickly broken down in the cell. The absence of functional BTK protein blocks B cell development and leads to a lack of antibodies, causing an increased susceptibility to infections in people with XLA.
Some people with XLA have large DNA deletions that remove one end of the BTK gene and all of a neighboring gene known as TIMM8A. Mutations in TIMM8A cause deafness-dystonia-optic neuronopathy (DDON) syndrome, which is characterized by hearing loss, vision problems, a decline in intellectual function (dementia), and involuntary muscle tensing (dystonia) or difficulty coordinating movements (ataxia). Individuals with large DNA deletions that include the BTK gene and the TIMM8A gene have the signs and symptoms of both XLA and DDON syndrome.
3. Other Names for This Gene
- AGMX1
- AT
- ATK
- BPK
- Bruton agammaglobulinemia tyrosine kinase
- Bruton's tyrosine kinase
- BTK_HUMAN
- dominant-negative kinase-deficient Bruton's tyrosine kinase
- IMD1
- MGC126261
- MGC126262
- PSCTK1
- tyrosine-protein kinase BTK
- XLA
References
- Alatzoglou KS, Dattani MT. Genetic causes and treatment of isolated growthhormone deficiency-an update. Nat Rev Endocrinol. 2010 Oct;6(10):562-76. doi:10.1038/nrendo.2010.147. Review.
- Broides A, Yang W, Conley ME. Genotype/phenotype correlations in X-linkedagammaglobulinemia. Clin Immunol. 2006 Feb-Mar;118(2-3):195-200.
- Conley ME, Farmer DM, Dobbs AK, Howard V, Aiba Y, Shurtleff SA, Kurosaki T. A minimally hypomorphic mutation in Btk resulting in reduced B cell numbers but no clinical disease. Clin Exp Immunol. 2008 Apr;152(1):39-44. doi:10.1111/j.1365-2249.2008.03593.x.
- Jyonouchi H, Geng L, Törüner GA, Vinekar K, Feng D, Fitzgerald-Bocarsly P.Monozygous twins with a microdeletion syndrome involving BTK, DDP1, and two othergenes; evidence of intact dendritic cell development and TLR responses. Eur JPediatr. 2008 Mar;167(3):317-21.
- Maas A, Hendriks RW. Role of Bruton's tyrosine kinase in B cell development.Dev Immunol. 2001;8(3-4):171-81. Review.
- Richter D, Conley ME, Rohrer J, Myers LA, Zahradka K, Kelecić J, Sertić J,Stavljenić-Rukavina A. A contiguous deletion syndrome of X-linkedagammaglobulinemia and sensorineural deafness. Pediatr Allergy Immunol. 2001Apr;12(2):107-11.
- Sedivá A, Smith CI, Asplund AC, Hadac J, Janda A, Zeman J, Hansíková H,Dvoráková L, Mrázová L, Velbri S, Koehler C, Roesch K, Sullivan KE, Futatani T,Ochs HD. Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes. J Clin Immunol. 2007 Nov;27(6):640-6.
- Smith CIE, Berglöf A. X-Linked Agammaglobulinemia. 2001 Apr 5 [updated 2016Aug 4]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K,Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University ofWashington, Seattle; 1993-2020. Available fromhttp://www.ncbi.nlm.nih.gov/books/NBK1453/
- Väliaho J, Smith CI, Vihinen M. BTKbase: the mutation database for X-linkedagammaglobulinemia. Hum Mutat. 2006 Dec;27(12):1209-17. Review.
- Wit JM, Kiess W, Mullis P. Genetic evaluation of short stature. Best Pract ResClin Endocrinol Metab. 2011 Feb;25(1):1-17. doi: 10.1016/j.beem.2010.06.007.Review.
